Glenmark launches first Fixed-Drug Combination in India to Manage Type 2 Diabetes
By Sanjay Maurya
News Highlights
- Type 2 diabetes is a medical condition that often demands the use of anti-diabetic medications or insulin to keep blood sugar levels under control.
- DCGI approved Glenmark’s drug for manufacture and commercialization in late September 2021.
- Glenmark’s Remogliflozin-Vildagiptin combination has been released for INR 16.50 per pill, to be taken twice daily.
Glenmark now become the first company to provide the fixed-dose combination (FDC) medicine Remogliflozin + Vildagliptin + Metformin at an accessible price for individuals with Type 2 Diabetes. India is the first country to receive this FDC medication. The Medication Controller General of India (DCGI) approved Glenmark’s drug for manufacture and commercialization in late September 2021.
Type 2 diabetes is a medical condition that often demands the use of anti-diabetic medications or insulin to keep blood sugar levels under control. Type 2 diabetes and its consequences, on the other hand, can be avoided if recognized and treated early.
Glenmark’s novel medicine combines two or more active pharmaceuticals in a single dose form, addressing the majority of the pathophysiology in uncontrolled Type 2 Diabetes management. Glenmark said in a statement that it has been at the forefront of providing low-cost access to the latest treatments for diabetic patients in India. According to the International Diabetes Federation (IDF), India has around 77 million individuals with diabetes.
DPP4i + SGLT2i + Metformin FDCs are well-known diabetes-control medications globally. Diabetic is a critical priority area for Glenmark, and we have been at the forefront of providing diabetes patients in India with access to the most up-to-date treatment alternatives, Alok Malik, Group Vice President, shared his thoughts. In late November, the DCGI granted the business permission for the product.
While existing products in the same medicine category have an average daily cost of therapy of INR 75, Glenmark’s Remogliflozin-Vildagiptin combination has been released for INR 16.50 per pill, to be taken twice daily, resulting in a per-day cost of treatment of INR 33 only. This price is 65 percent less than the other SGLT2 and DPP4 combo medications on the market, according to the company.
Remogliflozin + Vildagliptin + Metformin, according to Glenmark, will greatly increase access and provide patients in India with a world-class, well-researched combo medicine at an affordable price.
Must Read:-
- Top 10 pharma companies in the world
- Top 10 company of India 2021
- Top 10 logistic Companies in India 2021
- Top 10 automobile companies in India 2021
- Top 10 fastest growing industries in the world 2021
- Top 10 most charitable person in the world 2021
- Top 10 logistic Companies in India – 2021
- Top 10 Company in the Corporate World
- Top 5 Most Fuel Efficient Car In India
- Start Small and go Big: Low-Investment Business Ideas 2021
- Top 10 Electrical Company in India 2021
